Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

7.660 +0.420 (+5.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Shares of Beyond Meat, Inc. (NASDAQ: BYND) rose sharply in today’s pre-market trading as the company reported stronger-than-expected sales for its fourth quarter. 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
3D Systems Posts Downbeat Q4 Results, Joins Eventbrite, Lemonade And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Recursion Pharmaceuticals Stock Tuesday?
Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
10+ Stocks, ETFs To Ride On Nvidia's Record-Breaking Success
Shares of NVIDIA Corp rose 15% as quarterly earnings beat forecasts. CEO cites AI's role in company's growth. Tech sector up. ETFs benefit. 
Via Benzinga
Topics Artificial Intelligence ETFs Earnings
Exposures Artificial Intelligence Financial
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Etsy, Inc. 
Via Benzinga
These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours?
These companies are focused on next-gen technologies that could help transform the healthcare industry. 
Via The Motley Fool
NVIDIA Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NVIDIA Corporation (NASDAQ: NVDA) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 21, 2024. 
Via Benzinga
Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.
See which AI stocks the world's hottest AI chipmaker especially likes. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Did Nvidia Invest in These 5 Artificial Intelligence (AI) Stocks? Should You Buy Them, Too?
Nvidia's 13F revealed some interesting investments. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Host Public L(earnings) Call on February 27
From Recursion Pharmaceuticals
Via GlobeNewswire
Investors Are Piling Into Nvidia Stock. But Nvidia Is Investing in 5 Other AI Stocks.
Two of these stocks represent some of the best potential applications for AI technology. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Get Rich Quick With These 3 AI Stocks to Buy Now
Jump on the AI revolution with three AI stocks poised for rapid growth. Don't miss out on these potential wealth generators in the tech boom. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Has Invested in Arm Holdings and a Few Other Artificial Intelligence (AI) Stocks -- Should Investors Follow?
Nvidia released its 13F for the first time and caused numerous stocks to skyrocket. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Recursion Pharmaceuticals Stock Zoomed Higher on Thursday
A top name in the artificial intelligence world has put its money where its mouth is with this biotech. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 3 Up-and-Coming Stocks That Could Make Your February Unforgettable
Finding an up-and-coming stock worth investing in is harder than it used to be, but you don't have to look far if you check out this list. 
Via InvestorPlace
5 Stocks to Buy to Invest Like Nvidia
Do you want to invest like Nvidia? Here are the stocks to buy if you want to follow the chipmaker's methodology and focus on AI exposure. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 AI Stocks that Could be the Next Palantir
These niche AI stocks are using Palantir's ascent as a roadmap to market dominance in their respective fields. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Is Betting on SoundHound AI (SOUN) Stock
SOUN stock has been having a great last month, and a disclosure showing that Nvidia is betting on it, too, is sending SOUN even higher. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's Going On With Recursion Pharmaceuticals Stock On Thursday?
Recursion Pharmaceuticals' approach to drug discovery. NVIDIA's $75.9 million stake amplifies the impact of generative AI in identifying innovative treatments. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Is Betting Big on ARM Stock
Arm stock is up on Thursday after investors in the semiconductor company learned that graphics card company Nvidia holds a large stake in it. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nvidia Bolsters AI Leadership with Investment in Arm Holdings, Eyes Future Growth in Semiconductor Industry
Nvidia's investment portfolio includes stakes in Arm Holdings, SoundHound AI, and Recursion Pharmaceuticals. Despite failed acquisition, Arm's market valuation has soared to $130 billion. Significant... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nvidia Discloses Stakes In Arm, SoundHound AI, Nano-X And More
The AI chip leader revealed investments in its first-ever 13F SEC filing late Wednesday. 
Via Investor's Business Daily
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence Legal Regulatory
2 Cathie Wood Stocks With Jaw-Dropping Growth Potential
These two platform biotechs could revolutionize the field of biologically based products. 
Via The Motley Fool
Cathie Wood's Ark Invest Sheds $2.8M Worth Of Nvidia Shares Amid AI Hype, Picks Up Robinhood Stock Worth $1.3M
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.